Author: Ravi Shankar

Maroussi, Greece, November 13, 2026 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international diversified shipping company with a focus on the seaborne transportation of refined petroleum products and dry bulk commodities, today announced the following:

We will issue our unaudited results for the third quarter ended September 30, 2026, after the market close in New York on Monday, November 30, 2026.

An accompanying slide presentation of the third quarter 2026 financial results will be available on the Pyxis Tankers website, under the Presentations section of the Investor Relations page.

About Pyxis Tankers Inc.

Pyxis Tankers Inc. currently owns a modern fleet of six mid-sized eco-vessels engaged in the seaborne transportation of a broad range of refined petroleum products and dry-bulk commodities. The fleet consists of three MR product tankers, one Ultramax bulk carrier, and two sister-ship Kamsarmax bulk carriers, one of which is owned through a joint venture in which the Company holds a controlling interest. The Company is positioned to opportunistically expand and maximize its fleet of eco-efficient vessels due to significant capital resources, competitive cost structure, strong customer relationships and an experienced management team whose interests are aligned with those of its shareholders. For more information, visit: https://www.pyxistankers.com. The information on or accessible through the Company’s website is not incorporated into and does not form a part of this release.

Company

Pyxis Tankers Inc.
59 K. Karamanli Street
Maroussi, 15125 Greece
info@pyxistankers.com

Visit our website at https://www.pyxistankers.com

Company Contact

Fotis Giannakoulis
Chief Financial Officer
Tel: +1 917 291 7142 / +30 (210) 638 0200  
Email: ir@pyxistankers.com

Millicom (Tigo) signs agreement to acquire Entel Peru, expanding its presence across Latin America

The transaction expands Millicom’s presence in investment-grade markets and is expected to be accretive to equity free cash flow in the first year following completion. Closing is expected in early December, subject to customary closing conditions.

  

Luxembourg, November 13, 2026 – Millicom (NASDAQ: TIGO) today announced that it has signed an agreement to acquire Entel Peru for US$1,714 million, including lease liabilities, implying a transaction multiple of 5.0x estimated 2026 EBITDA, before synergies and integration costs. This transaction marks another important step in Millicom’s regional growth strategy and is expected to be funded through a combination of local financing and cash on hand. The purchase price will be paid in three installments: 65% at closing, 10% twelve months after closing, and 25% eighteen months after closing. The transaction is expected to close in early December 2026, subject to satisfaction of certain closing conditions.

Upon completion, the acquisition would expand Millicom’s footprint to 13 markets and further advance its strategy of geographic diversification, increasing its presence in investment-grade economies. Peru, which holds investment-grade sovereign ratings from Moody’s, S&P and Fitch, offers a market of more than 34 million people and an attractive foundation for long-term growth in connectivity and digital services.

Entel Peru’s established network, strong postpaid customer base and enterprise relationships provide an attractive platform for profitable growth. Following completion, Millicom intends to build on these strengths by applying its operational improvement capabilities, regional purchasing power and disciplined approach to capital allocation. The Group sees significant opportunities to improve efficiency, optimize working capital and strengthen cash generation, while preserving service quality and customer experience.

The acquisition would also create opportunities to expand higher-value services for consumers and businesses. Entel Peru’s access to an extensive fiber footprint through wholesale partnerships, combined with Millicom’s experience in mobile and home connectivity, would support capital-efficient growth in convergent services, stronger customer relationships and additional recurring revenues.

Millicom expects the transaction to be accretive to equity free cash flow in its first year following completion, consistent with the approach taken in its recent Telefónica acquisitions. Despite the anticipated closing late in the year, the Group expects year-end 2026 leverage to remain around 2.5x, including the acquisition. The transaction is not expected to adversely affect planned shareholder distributions and is expected to strengthen the Group’s capacity to support distributions over time through increased cash generation.

Marcelo Benitez, CEO of Millicom, commented: “We are very excited about entering Peru, a great country with tremendous potential and an important new chapter in our growth journey across Latin America. Over the past few years, we have demonstrated our ability to successfully integrate new operations, improve customer experience and deliver strong financial results. We have a proven playbook built around our Double-E strategy: delivering the best customer Experience with the greatest Efficiency. We are confident in our ability to replicate that success in Peru. Entel Peru brings a strong network, loyal customers and a talented team. Together, we see a great opportunity to invest in connectivity, bring better services and greater value to Peruvian consumers and businesses, and contribute to the country’s digital development. Our focus remains the same: disciplined execution, profitable growth and sustainable cash flow generation. We look forward to welcoming the Entel Peru team to the Millicom family and building a successful future together.”

Peru: An attractive platform for long-term growth

• A sizeable market with significant digital potential: With more than 34 million people, Peru offers a substantial customer base for mobile connectivity, home broadband and enterprise solutions. Millicom sees opportunities to deepen digital adoption and expand higher-value services for households and businesses.
• A growing economy with an attractive medium-term outlook: The IMF’s October 2026 projections anticipate economic growth of 2.9% in 2027 and 3.2% in 2028, with nominal GDP reaching approximately US$414 billion in 2027. Strong macroeconomic institutions, relatively low public debt and substantial international reserves provide a supportive foundation for long-term investment.
• Investment-grade credentials and international investor confidence: Peru holds investment-grade sovereign ratings of Baa1 from Moody’s, BBB from Fitch and BBB− from S&P. As of November 5, 2026, its J.P. Morgan sovereign bond spread stood at 121 basis points, approximately 43% below the Latin American benchmark, placing Peru among the region’s lowest sovereign-risk markets.
• Growing demand for recurring connectivity services: Mobile service revenues increased by 5.6% and fixed internet revenues by 5.8% in 2025, according to OSIPTEL. Postpaid and controlled-plan mobile subscriptions grew by 10.1%, highlighting an expanding market for recurring services and deeper customer relationships.
• Expanding fiber adoption across the country: Fiber connections grew by approximately 21% in 2025, with growth exceeding 26% outside Lima and Callao. This expansion supports opportunities to combine mobile and home broadband services, improve customer retention and bring advanced connectivity to more communities.
• A strong fit with Millicom’s capabilities: These market dynamics offer an attractive setting for Millicom to apply its regional scale, experience in convergent services and disciplined investment approach. Following completion, the Group would seek to translate this potential into profitable growth, stronger cash generation and lasting benefits for customers.

For further information, please contact:

Press:	Investors:
Sofia Corral, Director Corporate Communications press@millicom.com	Luca Pfeifer, VP of Investor Relations investors@millicom.com

About Millicom
Millicom (NASDAQ: TIGO) is a leading provider of fixed and mobile telecommunications services in Latin America. Through its TIGO® and Tigo Business® brands, the company provides a wide range of digital services and products, including TIGO ONEtv for pay TV, high-speed data, voice, and business-to-business solutions such as cloud and security. As of September 30, 2026, Millicom, including its Honduras Joint Venture and Chile associate, employed approximately 19,000 people and provided mobile and fiber-cable services through its digital highways to more than 65 million customers, with a fiber-cable footprint over 28 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg with principal executive offices in Doral, Florida.

ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) — The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

• Notification of managers’ transaction – Anthony Rosenberg – 13 November 2026 RSU vest
• Notification of managers’ transaction – Christina Ackermann – 13 November 2026 RSU vest
• Notification of managers’ transaction – Arshad Khanani – 13 November 2026 RSU vest
• Notification of managers’ transaction – Robert Warner – 13 November 2026 RSU vest

CAMBRIDGE, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.

Korro granted the new employee a nonstatutory stock option to purchase 1,000 shares of Korro’s common stock at an exercise price of $14.41 per share, the closing price per share of Korro’s common stock as reported by Nasdaq on the grant effective date, November 11, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of the employee’s start date, subject to the employee’s continued service with Korro through each applicable vesting date.

This grant was approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and was made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.  As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information  

Investor & Media Contact 
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update. 

“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder,” said Shawn Singh, President and Chief Executive Officer of Vistagen. “Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”

Corporate and Program Highlights

Phase 3 Development of Fasedienol in Social Anxiety Disorder

• FDA Type C Meeting Feedback: The U.S. Food and Drug Administration (FDA) provided constructive feedback regarding Vistagen’s potential Phase 3 study of fasedienol in adults with social anxiety disorder (SAD), including recommendations regarding use of the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint and interim assessments to assess whether acute effects of fasedienol could lead to longer-term overall functional improvement in patients as measured by the LSAS over time, consistent with the unique proposed mechanism of action and hypothesized treatment model for fasedienol. Feedback from the recent meeting also included FDA’s recognition of fasedienol’s reported safety profile and potential to benefit a broad population of patients with SAD. Based on the FDA’s feedback, Vistagen plans to focus future Phase 3 clinical development of fasedienol on the overall treatment of SAD (not only acute treatment) for the general SAD population.
• PALISADE-4 Phase 3 Study OLE: Announced preliminary positive data from the open-label extension (OLE) portion of PALISADE-4, the Company’s Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months, as measured by the LSAS. The Company believes placebo-controlled Phase 2 data and data from the OLE portion of its PALISADE Phase 3 trials conducted to date in everyday life settings have shown that acute treatment with fasedienol, administered as-needed at the patient’s discretion up to six times a day, has the potential to provide therapeutic benefit in anxiety-provoking situations over time.

Corporate Updates

• New Board Member: Appointed Douglas J. Williamson, MD to its Board of Directors, bringing decades of neuroscience drug development and commercialization experience from Acadia Pharmaceuticals, Eli Lilly, Lundbeck, Avadel Pharmaceuticals, and QurAlis.
• Cost Management Initiatives: Implemented targeted cost-management initiatives designed to prioritize capital allocation across prioritized clinical-stage programs and- extend operating runway.
• Psych Congress Presentation: Presented Phase 3 data demonstrating a positive efficacy signal for fasedienol in participants with very severe social anxiety disorder at Psych Congress 2026.

Financial Results for Fiscal Year 2027 Second Quarter Ended September 30, 2026

Research and development (R&D) expense: R&D expense was $6.6 million for the three months ended September 30, 2026, as compared to $15.9 million for the three months ended September 30, 2025. The decrease was primarily due to lower clinical development expenses following the completion of the open label extension portions of the Company’s PALISADE-3 and PALISADE-4 Phase 3 studies and the randomized and open label extension portions of its exploratory Phase 2 repeat dose study as well as reduced headcount-related expenses.

General and administrative (G&A) expense: G&A expense was $4.5 million for the three months ended September 30, 2026, as compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily due to higher consulting and professional fees, driven by higher legal fees, partially offset by lower compensation and related costs associated with reduced headcount-related expenses and lower stock-based compensation expense.

Net loss: Net loss was $10.7 million for the three months ended September 30, 2026, as compared to $19.4 million for the three months ended September 30, 2025.

Cash position: Cash, cash equivalents, and marketable securities were $20.0 million as of September 30, 2026. Based on current operating plans, Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are not expected to be sufficient to extend the Company’s cash runway for more than a year from now.

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen’s pherine pipeline currently consists of five investigational product candidates focused on improving the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause. Connect at www.Vistagen.com.

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding Vistagen’s beliefs about the potential regulatory path forward for fasedienol and its continued Phase 3 development in SAD, Vistagen’s ability to advance the broader potential of its pherine pipeline and preserve strategic flexibility needed to create long-term shareholder value, Vistagen’s interpretation of FDA feedback concerning future Phase 3 development plans for fasedienol, Vistagen’s belief about the meaningfulness of data from the OLE portion of PALISADE-4, and Vistagen’s belief that its cash resources will support operations into 2027 but are not expected to be sufficient to support operations for more than one year from the date of this press release. Forward-looking statements include all matters that are not historical facts and involve known and unknown risks that are difficult to predict. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would,” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Moreover, there can be no assurance that FDA feedback will result in a successful registrational pathway, that future clinical trials will demonstrate the safety and efficacy of fasedienol for either the overall or acute treatment of SAD, that existing clinical evidence and future study outcomes will be sufficient to support regulatory approval, or that Vistagen will obtain the financing necessary to advance its development plans. The FDA may require additional studies or information, and there can be no guarantee that fasedienol or any of Vistagen’s other product candidates will receive regulatory approval or be commercially successful. Other factors that may cause actual results to differ materially include, without limitation, risks and uncertainties relating to conducting future clinical trials as currently expected or at all; Vistagen’s ability to successfully employ cash preservation measures and/or secure adequate financing for its operations, including financing or collaborative support for continued clinical development of its product candidates; Vistagen’s dependence on third-party collaborators for the development, regulatory approval, and/or commercialization of its product candidates and other aspects of its business, which are outside of Vistagen’s full control; the scope and enforceability of Vistagen’s patents, including patents related to Vistagen’s pherine product candidates; fluctuating costs of materials and other resources and services required to conduct Vistagen’s ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; and other technical and unexpected hurdles in the development, manufacture and commercialization of Vistagen’s product candidates. These risks and others are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Annual Report on Form 10-K for the period ended March 31, 2026, and Quarterly Report on Form 10-Q for the period ended September 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and par value amounts)
	September 30, 2026				March 31, 2026
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	10,892			$	30,789
Marketable securities		9,142				14,614
Prepaid expenses and other current assets		2,260				1,540
Total current assets		22,294				46,943
Property and equipment, net		325				427
Right-of-use asset – operating lease		513				801
Other assets		289				393
Total assets	$	23,421			$	48,564
LIABILITIES AND STOCKHOLDERS’EQUITY
Current liabilities:
Accounts payable	$	1,084			$	1,535
Accrued expenses		6,639				8,755
Note payable		—				96
Deferred revenue		96				1,710
Operating lease obligation – current portion		610				699
Total current liabilities		8,429				12,795
Operating lease obligation – non-current portion		—				249
Total liabilities		8,429				13,044
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2026 and March 31, 2026; no shares outstanding at September 30, 2026 and March 31, 2026		—				—
Common stock, $0.001 par value; 325,000,000 shares authorized at September 30, 2026 and March 31, 2026; 45,595,380 and 39,624,839 shares issued at September 30, 2026 and March 31, 2026, respectively		46				40
Additional paid-in capital		520,012				516,767
Treasury stock, at cost, 4,522 shares of common stock held at September 30, 2026 and March 31, 2026		(3,968	)			(3,968	)
Accumulated other comprehensive loss		(11	)			(2	)
Accumulated deficit		(501,087	)			(477,317	)
Total stockholders’ equity		14,992				35,520
Total liabilities and stockholders’ equity	$	23,421			$	48,564

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share amounts)
	Three Months Ended September 30,								Six Months Ended September 30,
		2026				2025				2026				2025
Revenues:
Sublicense and other revenue	$	138			$	258			$	1,614			$	502
Total revenues		138				258				1,614				502
Operating expenses:
Research and development		6,554				15,915				17,459				27,693
General and administrative		4,521				4,396				8,439				8,667
Total operating expenses		11,075				20,311				25,898				36,360
Loss from operations		(10,937	)			(20,053	)			(24,284	)			(35,858	)
Other income, net:
Interest income, net		198				630				515				1,342
Other income		(1	)			6				(1	)			4
Loss before income taxes		(10,740	)			(19,417	)			(23,770	)			(34,512	)
Income taxes		—				—				—				—
Net loss	$	(10,740	)		$	(19,417	)		$	(23,770	)		$	(34,512	)
Unrealized gain (loss) on marketable securities		(4	)			13				(9	)			14
Comprehensive loss	$	(10,744	)		$	(19,404	)		$	(23,779	)		$	(34,498	)
Basic and diluted net loss per common share	$	(0.24	)		$	(0.54	)		$	(0.54	)		$	(1.02	)
Weighted average common shares outstanding, basic and diluted		44,440,372				35,749,160				43,714,263				33,850,346

Investor Inquiries:
IR@vistagen.com 

Media Inquiries:
Media@vistagen.com 

ST. LOUIS, Nov. 13, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2027 second quarter ended September 30, 2026.

Q2 2027 Financial Key Items (all comparisons to the prior year quarter)

• Operating income from continuing operations of $528,673 compared to $280,432 in the prior year quarter, an increase of approximately 89%  
• Income from continuing operations was $403,202 or $0.06 per share compared to $366,528 or $0.05 per share in the prior year quarter
• Net income was $366,249, or $0.05 per share, compared to $263,407, or $0.04 per share in the previous year quarter
• Operating EBITDA (excluding investment portfolio income) was $531,973 compared to $284,893 in the prior year quarter
• Insurance commission and fee revenue was $4,497,423 compared to $4,391,678 in the prior year period, an increase of 2%

Management Comments
Timothy M. Klusas, TMA’s Chief Executive Officer, commented, “We were very pleased with the increases in operating income and Operating EBITDA this quarter. As we stated in prior comments after financial results, we increased marketing staff to the insurance business to address our effort to further grow and develop our business, and the last vacant role was filled during the first fiscal quarter ending in June. Our results have been encouraging, and both carriers and agencies responded favorably to the added resources and capabilities of our team.”     

Klusas continued, “In addition to the investment in additional marketing staff, we identified and implemented new revenue streams for our call center that were initiated during the quarter ending in June and fully implemented in this quarter. Lastly, our annuity business within the insurance distribution business continued to perform well. It also benefited from a change in one carrier’s compensation agreement. Beginning this year, that carrier pays monthly based on production rather than an annual bonus tied to a full-year target. We expect the year-over-year timing difference to even out by the end of next quarter, when the annual payment was historically earned.”

Q2 2027 Second Quarter Financial Review

• Insurance commissions and fee revenue were $4,497,423 compared to $4,391,678 in the prior year quarter, an increase of over 2%.
• Net operating revenue (gross profit) for the quarter was $1,175,452 compared to net operating revenue (gross profit) of $892,467 in the prior year quarter, an increase of over 32%.     
• Operating expenses increased slightly this quarter to $646,779 from $612,035 in the prior year quarter, primarily due to increases in compensation, travel and insurance.   
• The Company reported operating income from continuing operations of $528,673 compared to $280,432, in the prior fiscal year quarter, due to the factors noted above.
• Net income was $366,249, or $0.05 per share, compared to $263,407, or $0.04 per share in the previous year quarter.
• Operating EBITDA (excluding investment portfolio income) of $531,973 was an increase from the prior year quarter of $284,893. A note reconciling operating EBITDA to operating income can be found at the end of this release.
• Investment gain (loss), net (from non-operating investment portfolio) for the quarter was $6,279 as compared with $155,096 in the previous year quarter.  
• Income from continuing operations was $403,202 or $0.06 per share compared to $366,528 or $0.05 per share in the prior year quarter. The increase was due to higher operating income from continuing operations but offset by higher non-operating investment gains in the prior year quarter,

On May 15, 2026, the Company announced it had sold to an unaffiliated purchaser substantially all of the equipment assets of its construction business, Empire Construction, Inc. and all the real property associated with the Empire Construction business.  The Company has elected to classify the construction business as a discontinued operation, and amounts may differ from the fiscal year 2026 financials as a result.

Balance Sheet Information

• TMA’s balance sheet on September 30, 2026, reflected cash and cash equivalents of $3.8 million, working capital of $6.6 million, and shareholders’ equity of $6.7 million, compared to cash and cash equivalents of $2.0 million, working capital of $5.3 million, and shareholders’ equity of $5.7 million as of September 30, 2025.

About The Marketing Alliance, Inc.

Headquartered in St. Louis, MO, TMA provides support to independent insurance brokerage agencies, with a goal of integrating insurance and “insuretech” engagement platforms to provide members value-added services on a more efficient basis than they can achieve individually.

Investor information can be accessed through the shareholder section of TMA’s website at: 
http://www.themarketingallianceinc.com.

TMA’s common stock is quoted on the OTC Markets (http://www.otcmarkets.com) under the symbol “MAAL”.

Forward Looking Statements
Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect TMA’s business and prospects. Examples of forward-looking statements include, among others, statements we make regarding our expectations of growth based upon our investments, including adding personnel, in our insurance business, and our plans to reduce expenses. Any forward-looking statements contained in this press release represent our estimates, expectations or intentions only as of the date hereof, or as of such earlier dates as are indicated, and should not be relied upon as representing our views as of any subsequent date. These statements involve a number of risks and uncertainties, including, but not limited to, expectations of the economic environment, material adverse changes (including the effects of inflation) in economic conditions in the markets we serve and in the general economy; the ways that insurance carriers may react in their underwriting policies and procedures to the continuing risks they perceive from public health matters; our reliance on a limited number of insurance carriers and any potential termination of those relationships or failure to develop new relationships; privacy and cyber security matters and our ability to protect confidential information; future state and federal regulatory actions and conditions in the states in which we conduct our business; our ability to work with carriers on marketing, distribution and product development; pricing and other payment decisions and policies of the carriers in our insurance distribution business, and changes in the public securities markets that affect the value of our investment portfolio. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Contact:
The Marketing Alliance, Inc.	-OR-	The Equity Group Inc.
Timothy M. Klusas, President		Jeremy Hellman, Vice President
(314) 275-8713		(212) 836-9626
tklusas@themarketingalliance.com		jhellman@equityny.com
www.TheMarketingAllianceinc.com

CONSOLIDATED STATEMENTS OF OPERATIONS
	Three Months Ended								Six Months Ended
	September 30,								September 30,
		2026				2025				2026				2025
Insurance commission and fee revenue	$	4,497,423			$	4,391,678			$	9,251,399			$	9,071,982
Insurance distributor related expenses:
Distributor bonuses and commissions		2,750,795				2,959,217				5,871,113				6,147,299
Business processing and distributor costs		571,176				539,130				1,134,004				1,058,756
Depreciation		–				864				864				1,728
Total costs of revenues		3,321,971				3,499,211				7,005,981				7,207,783
Net operating revenue		1,175,452				892,467				2,245,418				1,864,199
Total general and administrative expenses		646,779				612,035				1,316,495				1,243,592
Operating income from continuing operations		528,673				280,432				928,923				620,607
Other income (expense):
Investment gains (losses), net		6,279				155,096				136,780				257,670
Interest		–				–								(12,214	)
Income from continuing operations before provision for income taxes		534,952				435,528				1,065,703				866,063
Income tax expense		131,750				69,000				258,450				151,300
Income from continuing operations		403,202				366,528				807,253				714,763
Discontinued operations:
Loss from discontinued operations, net of income taxes		(36,953	)			(103,121	)			(134,534	)			(175,731	)
Gain on disposal of discontinued operations, net of income taxes		–				–				660,042				–
Net gain (loss) from discontinued operations		(36,953	)			(103,121	)			525,508				(175,731	)
Net Income	$	366,249			$	263,407			$	1,332,761			$	539,032
Income (loss) per common share – basic and diluted:
Continuing operations	$	0.06			$	0.05			$	0.12			$	0.10
Discontinued operations		(0.01	)			(0.01	)			0.08				(0.02	)
Net income (loss)	$	0.05			$	0.04			$	0.19			$	0.07
Weighted-average common shares outstanding – basic and diluted		6,850,566				7,240,651				6,831,698				7,278,594

CONSOLIDATED BALANCE SHEETS
		2026				2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	3,786,325			$	1,960,775
Equity securities		1,586,120				2,261,437
Accounts receivable		6,927,512				7,726,955
Notes receivable		19,402				–
Prepaid expenses and other current assets		200,808				162,235
Assets related to discontinued operations		15,745				315,113
Total current assets		12,535,912				12,426,515
PROPERTY AND EQUIPMENT, net		89,325				33,413
OTHER ASSETS
Operating lease right-of-use assets		418,135				534,037
Other assets related to discontinued operations		–				520,551
Total other assets		418,135				1,054,588
	$	13,043,372			$	13,514,516
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	5,486,658			$	6,395,403
Deferred Revenue		331,400				278,300
Current portion of operating lease liability		110,581				154,261
Liabilities related to discontinued operations		677				274,425
Total current liabilities		5,929,316				7,102,389
LONG-TERM LIABILITIES
Operating lease liability, net of current portion		313,838				384,524
Other liabilities related to discontinued operations		–				179,262
Deferred taxes		56,300				149,200
Total long-term liabilities		370,138				712,986
Total liabilities		6,299,454				7,815,375
COMMITMENTS AND CONTINGENCIES (NOTE 13)
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 10,000,000 shares authorized, no shares issued and outstanding		–				–
Common stock, no par value; 50,000,000 shares authorized,
6,898,392 shares issued and outstanding September 30, 2026
7,188,088 shares issued and outstanding September 30, 2025	$	1,282,355			$	1,176,441
Treasury Stock		(1	)			(209,112	)
Retained earnings		5,461,564				4,731,812
Total shareholders’ equity		6,743,918				5,699,141
	$	13,043,372			$	13,514,516

Note – Operating EBITDA (excluding investment portfolio income)

	Three Months Ended								Six Months Ended
EBITDA Calculation	September 30,								September 30,
		2026				2025				2026				2025
Operating Income from Continuing Operations	$	528,673			$	280,432			$	928,923			$	620,607
Add:
Depreciation/Amortization Expense	$	3,300			$	4,461			$	7,762			$	8,923
EBITDA (Excluding Investment Portfolio Income)	$	531,973			$	284,893			$	936,685			$	629,530

The Company elects not to include investment portfolio income because the Company believes it is non-operating in nature.

The Company uses Operating EBITDA as a measure of operating performance. However, Operating EBITDA is not a recognized measurement under U.S. generally accepted accounting principles, or GAAP, and when analyzing its operating performance, investors should use Operating EBITDA in addition to, and not as an alternative for, income as determined in accordance with GAAP. Because not all companies use identical calculations, its presentation of Operating EBITDA may not be comparable to similarly titled measures of other companies and is therefore limited as a comparative measure. Furthermore, as an analytical tool, Operating EBITDA has additional limitations, including that (a) it is not intended to be a measure of free cash flow, as it does not consider certain cash requirements such as tax payments; (b) it does not reflect changes in, or cash requirements for, its working capital needs; and (c) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and Operating EBITDA does not reflect any cash requirements for such replacements, or future requirements for capital expenditures or contractual commitments. To compensate for these limitations, the Company evaluates its profitability by considering the economic effect of the excluded expense items independently as well as in connection with its analysis of cash flows from operations and through the use of other financial measures.

The Company believes Operating EBITDA is useful to an investor in evaluating its operating performance because it is widely used to measure a company’s operating performance without regard to certain non-cash or unrealized expenses (such as depreciation and amortization) and expenses that are not reflective of its core operating results over time. The Company believes Operating EBITDA presents a meaningful measure of corporate performance exclusive of its capital structure, the method by which assets were acquired, and non-cash charges and provides additional useful information to measure performance on a consistent basis, particularly with respect to changes in performance from period to period.

NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the third quarter and nine months ended September 30, 2026, and provided a corporate update.

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.
“Our ambition is to position Indaptus for its next phase of growth by pursuing innovative opportunities with meaningful potential. We intend to move forward with energy and conviction, while maintaining a disciplined approach to capital allocation and focusing our resources on opportunities that we believe can create meaningful long-term value for our shareholders.”

Key Highlights

• September 2026 private placement. On September 8, 2026, the Company entered into a private placement for 20,338,974 shares of common stock and aggregate gross proceeds of approximately $24.0 million. The transaction closed on October 16, 2026; approximately $20.5 million had been received by September 30, 2026, and the remaining approximately $3.5 million was received in October. The Company currently intends to use the net proceeds from the Private Placement for working capital, research and development and other general corporate purposes, which may include early-stage research and preclinical evaluation of a potential neurotechnology and neural-network-based device for certain sleep-related conditions, with a view toward a potential future FDA submission.
• Liquidity position. As of September 30, 2026, the Company had approximately $26.6 million in cash and cash equivalents and $4.0 million in short-term investments, consisting of certificates of deposit that are redeemable on demand. In addition, the Company received approximately $3.5 million in remaining proceeds from the September 2026 Private Placement in October 2026. Based on its current operating plan, management believes that these resources provide sufficient liquidity to fund the Company’s anticipated operating expenses and capital expenditure requirements and support its planned research and development activities.

Financial Highlights for the Third Quarter and Nine Months Ended September 30, 2026

Research and development expenses decreased 82% to approximately $0.3 million for the third quarter of 2026, compared with approximately $1.5 million for the same period in 2025. For the first nine months of 2026, research and development expenses decreased 83% to approximately $1.1 million, compared with approximately $6.5 million in 2025. The decreases were primarily attributable to lower clinical costs related to the Decoy20 Phase 1 study and lower payroll and related expenses following reductions in headcount and base salaries.

General and administrative expenses decreased 24% to approximately $0.9 million for the third quarter of 2026, compared with approximately $1.1 million for the same period in 2025. For the first nine months of 2026, general and administrative expenses decreased 23% to approximately $4.0 million, compared with approximately $5.2 million in 2025. The decreases were primarily attributable to lower expenses related to the transition of management and lower payroll and related expenses following reductions in headcount and base salaries. For the nine months ended September 30, 2026, these decreases were partially offset by a $0.5 million termination fee incurred in connection with the termination of the ATM Agreement.
Net loss decreased to approximately $1.0 million for the third quarter of 2026, compared with approximately $3.0 million for the same period in 2025. For the first nine months of 2026, net loss decreased to approximately $5.4 million, compared with approximately $12.7 million in 2025. Basic and diluted net loss per share was approximately $0.01 for the third quarter of 2026 and $0.06 for the first nine months of 2026, compared with $2.98 and $18.48, respectively, for the corresponding periods in 2025.

As of September 30, 2026, the Company had approximately $30.6 million in cash, cash equivalents and short-term investments. Net cash used in operating activities was approximately $10.4 million for the nine months ended September 30, 2026. The Company received approximately $20.5 million in proceeds from the September 2026 private placement during the third quarter. As the transaction closed on October 16, 2026, these proceeds were recorded as “Proceeds received pending share issuance” under current liabilities on the September 30, 2026 condensed consolidated balance sheet.

About Indaptus Therapeutics

Indaptus Therapeutics is a biotechnology company dedicated to immunotherapy research. The Company’s patented Decoy technology uses attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate multiple components of innate and adaptive immunity while reducing systemic toxicity. The Company is evaluating the Decoy platform and existing therapeutic assets, including potential licensing, partnership and other strategic opportunities.

The Company seeks to better understand the relationship among sleep, physical recovery, neurological function and immune status, which could potentially support future immunotherapy evaluation, patient recovery monitoring and biomarker research. The Company is also evaluating complementary research initiatives, including early-stage research and preclinical evaluation of a potential neurotechnology and neural-network-based device for certain sleep-related conditions. The scope and timing of any such activities will depend on scientific validation, strategic fit, market opportunities, available resources, regulatory considerations and other business factors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s expectations, beliefs and intentions concerning, among other things, the Company’s ability to use the proceeds from the September 2026 private placement for working capital, research and development and other general corporate purposes; the potential scope and progress of early-stage research and preclinical evaluation of a potential neurotechnology and neural-network-based device for certain sleep-related conditions and any potential future FDA submission; the Company’s review of the Decoy platform and Decoy20; potential licensing, partnership and other strategic opportunities; research collaborations and complementary research initiatives; the Company’s strategic review and potential investments in or acquisitions of operating businesses; the sufficiency of the Company’s cash, cash equivalents and short-term investments to fund its activities; the Company’s cash runway and ability to raise additional capital; and the Company’s future results of operations and financial condition.

Forward-looking statements can be identified by words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or “anticipate,” or their negatives or variations, or by the fact that the statements do not relate strictly to historical matters. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially, including: the Company’s limited operating history and history of losses; the need for, and ability to raise, additional capital; dilution from future financings; the Company’s ability to identify, negotiate and complete strategic transactions and realize anticipated benefits; risks associated with investments, acquisitions and expansion into new research or business areas; the absence of active clinical development programs and the discontinuation and wind-down of Decoy20 clinical activities; uncertain outcomes and costs of research, preclinical and clinical development; the possibility that any research initiative or potential product candidate may not demonstrate sufficient scientific merit or obtain regulatory approval; reliance on third parties; competition; protection of proprietary or licensed technology; compliance with healthcare, securities and other laws; information technology failures, cyberattacks and cybersecurity deficiencies; Nasdaq continued-listing risks; stock-price volatility; and unfavorable global economic conditions.

These and other important factors discussed under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and in the Company’s other filings with the Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statement to reflect subsequent events or circumstances.

Contact: investors@indaptusrx.com 

INDAPTUS THERAPEUTICS, INC.
Unaudited Condensed Consolidated Balance Sheets
		As of September 30,				As of December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	26,604,443			$	8,507,628
Short-term investments			4,000,000				–
Prepaid expenses and other current assets			607,542				802,540
Total assets		$	31,211,985			$	9,310,168
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and other current liabilities		$	329,926			$	6,158,575
Proceeds received pending share issuance (Note 6h)			20,549,933				–
Total liabilities			20,879,859				6,158,575
Commitments and contingencies (Note 7)			–
Stockholders’ equity:
Common stock: $0.01 par value, 1,000,000,000 and 200,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 133,242,324 shares issued and outstanding as of September 30, 2026 and 2,167,324 shares issued and outstanding as of December 31, 2025			1,332,424				21,674
Preferred stock: $0.01 par value, 5,000,000 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued and outstanding as of September 30, 2026 and 1,000,000 shares issued and outstanding as of December 31, 2025			–				10,000
Additional paid-in capital			95,672,510				84,408,018
Accumulated deficit			(86,672,808	)			(81,288,099	)
Total stockholders’ equity			10,332,126				3,151,593
Total liabilities and stockholders’ equity		$	31,211,985			$	9,310,168

^{* Share and per-share amounts have been retroactively adjusted for the one-for-28 reverse stock split effected in June 2025.}

INDAPTUS THERAPEUTICS, INC.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Operating expenses:
Research and development		$	271,204			$	1,517,723			$	1,125,465			$	6,495,677
General and administrative			864,663				1,130,764				3,978,854				5,182,132
Total operating expenses			1,135,867				2,648,487				5,104,319				11,677,809
Loss from operations			(1,135,867	)			(2,648,487	)			(5,104,319	)			(11,677,809	)
Other income (expense):
Warrant repricing			–				–				(410,154	)			–
Change in fair value of convertible promissory notes			–				(365,718	)			–				(1,153,421	)
Other income, net			87,089				39,088				129,764				94,764
Total other income (expense), net			87,089				(326,630	)			(280,390	)			(1,058,657	)
Net loss		$	(1,048,778	)		$	(2,975,117	)		$	(5,384,709	)		$	(12,736,466	)
Net loss per share, basic and diluted		$	(0.01	)		$	(2.98	)		$	(0.06	)		$	(18.48	)
Weighted average number of shares basic and diluted			133,242,324				997,038				87,494,438				689,174

^{* Share and per-share amounts have been retroactively adjusted for the one-for-28 reverse stock split effected in June 2025.}

INDAPTUS THERAPEUTICS, INC.
Unaudited Condensed Consolidated Statements of Cash Flows
		For the Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities:
Net loss		$	(5,384,709	)		$	(12,736,466	)
Adjustments to reconcile net loss to net cash (used in)  operating activities:
Stock-based compensation			171,269				572,268
Change in fair value of convertible promissory note			–				1,153,421
Warrant repricing			410,154				–
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			257,472				463,902
Accounts payable and other current liabilities			(5,828,649	)			(1,084,078	)
Operating lease right-of-use asset and liability, net			–				(1,790	)
Net cash (used in) operating activities			(10,374,463	)			(11,632,743	)
Cash flows from investing activities:
Certificates of deposit			(4,000,000	)			–
Net cash (used in) investing activities			(4,000,000	)			–
Cash flows from financing activities:
Proceeds from issuance of convertible promissory notes			–				5,714,800
Proceeds from issuance of shares of common stock and warrants			12,000,000				6,397,042
Proceeds from advance related to future financing			20,549,933				–
Issuance costs			(78,655	)			(440,213	)
Net cash provided by financing activities			32,471,278				11,671,629
Net increase in cash and cash equivalents			18,096,815				38,886
Cash and cash equivalents, beginning of period			8,507,628				5,786,753
Cash and cash equivalents, end of period		$	26,604,443			$	5,825,639
Noncash investing and financing activities:
Settlement of convertible debt		$	–			$	6,868,221
Issuance of commitment shares		$	–			$	109
Conversion of Series AA and Series AAA preferred stock		$	1,110,000			$	–

• Reports Q3 2026 GAAP Net Loss of $14.0 Million and First Nine Months 2026 GAAP Net Loss of $35.0 Million
• Reports Q3 2026 Adjusted Net Loss of $10.2 Million and First Nine Months 2026 Adjusted Net Loss of $23.5 Million (Non-GAAP)
• Ended Quarter with $9.2 Million in Cash and Cash Equivalents; Raised Approximately $6.0 Million in Gross Proceeds During the Quarter in a Warrant Inducement Transaction
• Issued Purchase Orders for Bodies and Chassis for Initial Production Vehicles and Entered into a Strategic Partnership Agreement with Shanghai Launch Automotive Technology
• Raised Approximately $23.1 Million in Gross Proceeds in the First Nine Months of 2026 Through a Public Offering and Warrant Inducements and Exercises, Plus Approximately $2.3 Million in Net Proceeds Under the Equity Line of Credit

CARLSBAD, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Aptera Motors Corp. (NASDAQ: SEV) (“Aptera” or the “Company”), a solar mobility company advancing ultra-efficient transportation, today reported its financial results for the third quarter and nine months ended September 30, 2026.

“In the third quarter we started the process of procuring parts for our first production vehicles. We also entered into a strategic partnership with Launch to support manufacturing and contract engineering, which we believe has helped lower our estimated capital needs to reach start of production and, most importantly, the capital we estimate is required to reach a production rate at which we believe we could fund ongoing operations from vehicle sales. Research and development spending more than doubled from the prior-year quarter as we directed our resources to vehicle validation and production readiness,” said Chris Anthony, Co-CEO of Aptera.

Third Quarter and First Nine Months 2026 Financial Highlights

(In thousands, except per share data)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2026	2025	2026	2025
GAAP net loss	$(13,968)	$(5,489)	$(35,046)	$(28,427)
Adjusted net loss (Non-GAAP)*	$(10,171)	$(3,013)	$(23,547)	$(10,165)
GAAP net loss per share, basic and diluted	$(0.35)	$(0.23)	$(0.96)	$(1.21)
Adjusted net loss per share, basic and diluted (Non-GAAP)*	$(0.25)	$(0.13)	$(0.65)	$(0.43)
Key Financial Data:
Operating expenses	$13,650	$7,942	$35,146	$33,009
Other income (expense), net	$(318)	$2,453	$100	$4,582

*See “Use of Non-GAAP Financial Measures” and reconciliation table below.

Business Update

During the third quarter of 2026, the Company announced a partnership with RepairPal to provide certified service for its customers nationwide, and TÜV Rheinland independently measured more than 4 kilowatt-hours of usable solar energy delivered to the vehicle’s battery on each of three test days. In August 2026, the Company ordered major parts for its initial production vehicles.

In August 2026, the Company entered into a Strategic Partnership Agreement with Shanghai Launch Automotive Technology Co., Ltd. (“Launch”), under which Launch will serve as a manufacturing and contract-engineering partner and perform manufacturing, engineering, tooling, testing, and related work. The agreement covers up to RMB 300 million in services, two-thirds payable in cash and one-third through warrants to purchase Class B Common Stock. The Company plans to begin building and delivering production vehicles as soon as practicable, subject to timely financing and regulatory approvals.

As of September 30, 2026, the Company had more than 49,000 reservations for its vehicle.

Liquidity

As of September 30, 2026, the Company had $9.2 million in cash and cash equivalents, including $4.1 million of refundable reservation fees collected from reservation holders.

During the first nine months of 2026, the Company raised approximately $23.1 million in gross proceeds through a public offering and warrant inducements and exercises, plus approximately $2.3 million in net proceeds under its equity line of credit. Since quarter end, the Company has raised approximately $6.0 million in gross proceeds through a registered direct offering and concurrent private placement, and approximately $0.6 million in net proceeds under its equity line of credit and at-the-market facility. The Company currently estimates it will need approximately $25 million to reach start of series production, including certain tooling and equipment, and approximately $65 million in total to reach a production rate of 500 vehicles per month, subject to obtaining timely financing on acceptable terms, supplier performance and regulatory approvals. The Company intends to use the net proceeds from the November 2026 registered direct offering toward these requirements.

The Company’s existing cash is not sufficient to fund its operations for the next twelve months, and substantial doubt about its ability to continue as a going concern has not been alleviated. Additional details regarding the Company’s going concern assessment are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Use of Non-GAAP Financial Measures

This press release includes Adjusted Net Loss and Adjusted Net Loss Per Share, which are non-GAAP financial measures. We define Adjusted Net Loss as GAAP net loss, excluding (i) non-cash stock-based compensation expense and (ii) the litigation settlement charge related to the Company’s previously disclosed litigation with Zaptera USA, Inc., which was settled and dismissed with prejudice in April 2026. We believe that these non-GAAP measures, when viewed in conjunction with our GAAP results, provide a more complete understanding of our core operating performance and trends, as these adjustments remove non-cash expenses and a discrete, non-recurring charge related to the settlement of the Zaptera litigation.

These non-GAAP measures are presented in addition to, and not as a substitute for, GAAP results. Non-GAAP measures have material limitations and may not be comparable to similarly titled measures of other companies. We encourage investors to review these measures together with our GAAP results and the reconciliations provided.

(Unaudited) Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss

(In thousands, except share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2026	2025	2026	2025
GAAP Net Loss	$(13,968)	$(5,489)	$(35,046)	$(28,427)
Add: stock-based compensation (G&A)	1,900	1,099	5,535	12,386
Add: stock-based compensation (R&D)	1,897	1,377	5,318	5,876
Add: Zaptera litigation settlement charge	—	—	646	—
Non-GAAP adjusted net loss	$(10,171)	$(3,013)	$(23,547)	$(10,165)
Weighted-Average Shares Outstanding	40,238,995	23,609,592	36,439,109	23,485,359
GAAP net loss per share, basic and diluted	$(0.35)	$(0.23)	$(0.96)	$(1.21)
Non-GAAP adjusted net loss per share, basic and diluted	$(0.25)	$(0.13)	$(0.65)	$(0.43)

About Aptera Motors Corp.

Aptera Motors Corp. (Nasdaq: SEV) is a solar mobility company driven by a mission to advance the future of efficient transportation. Its flagship vehicle is conceived to be a paradigm-shifting solar electric vehicle that leverages breakthroughs in aerodynamics, material science, and solar technology to pursue new levels of efficiency. As a public benefit corporation, Aptera is committed to building a sustainable business that positively impacts its stakeholders and the environment. Aptera is headquartered in Carlsbad, California. For more information, please visit www.aptera.us.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our plans and expectations for validation builds, the expansion of our validation fleet and testing program, timing of component deliveries, anticipated commencement of assembly, future production, manufacturing and assembly scale-up, our estimated capital requirements, our expected capital needs and financing plans, the potential exercise of outstanding warrants, our ability to access and utilize our equity line of credit and at-the-market program, the anticipated benefits of our Strategic Partnership Agreement with Launch, our path to low-volume production, the timing and scope of customer deliveries, and our overall business strategy and outlook. These forward-looking statements are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “plan,” “seek,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall,” “continue,” “advancing,” “scaling” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Aptera’s control. These risks include, among others, supply chain delays and disruptions; changes in trade policies, including tariffs; our ability to hire key personnel; the possibility that reservations may be cancelled or otherwise not result in binding purchase orders; the feasibility and timing of scaling our manufacturing processes; the availability and timing of required capital, and market conditions affecting financing; regulatory approvals and compliance, including compliance with Federal Motor Vehicle Safety Standards; our ability to continue as a going concern absent additional financing; our ability to access capital under our equity line of credit, our at-the-market offering program and other sources on acceptable terms and timing; our reliance on Launch, a manufacturing and contract-engineering partner located in the People’s Republic of China, and the related cross-border, regulatory and currency risks; dilution resulting from the issuance and exercise of warrants, including warrants issued to Launch; our dependence on successful validation builds and timely component deliveries to achieve any production milestones; the previously disclosed material weaknesses in our internal control over financial reporting and the timing and cost of remediation; the ongoing SEC investigation; and other risks described in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and our other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release represent Aptera’s views as of the date of this press release. Aptera anticipates that subsequent events and developments will cause its views to change. Aptera undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Aptera’s views as of any date subsequent to the date of this press release.

Contacts

Investor Relations:
Aptera Motors Corp.
ir@aptera.us

Media Contact:
media@aptera.us

EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 10, 2026, the compensation committee of the Company’s board of directors granted one new non-executive employee 21,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

CONTACT: Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

SARATOGA SPRINGS, N.Y., Nov. 13, 2026 (GLOBE NEWSWIRE) — Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first three months of fiscal year 2027.

Net sales for the three months ended September 30, 2026 and 2025 were $10,608,945 and $9,092,876, respectively. Net income for the three months ended September 30, 2026 was $2,189,509 or $0.77 and $0.75 per share, basic and diluted, compared to net income of $2,169,836 or $0.80 and $0.76 per share, basic and diluted, for the three months ended September 30, 2025.

The total backlog at September 30, 2026 was $126.7 million, compared to approximately $141.1 million at September 30, 2025. New orders received in the first three months of fiscal year 2027 were $2.6 million as compared to $10.5 million new orders received in the first three months of fiscal year 2026.

Mr. David O’Neil, President and CEO, commented,

The Company had a strong start to the year, delivering notable top-line revenue growth in the first quarter. To build on this momentum, management continues to be focused on bookings execution, managing costs, and continuing to convert existing opportunities into revenue. While gross profits remain sensitive to our overall product mix, we are actively managing our programs to help build long-term value. Our progress is driven by the dedication and expertise of our employees. The team remains focused on the opportunities ahead and management is committed to executing on our priorities as we move through fiscal year 2027.

Espey’s primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the internet at www.espey.com.

For further information, contact Ms. Kaitlyn O’Neil at invest@espey.com.

This press release may contain certain statements that are “forward-looking statements” and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s current expectations or beliefs concerning future events. The matters covered by these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.